He, Yonghan

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 688

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

He, Y., Zhang, X., Chang, J., Kim, H.-N., Zhang, P., Wang, Y., Khan, S., Liu, X., Zhang, X., Lv, D., et al. (2020) · Nature Communications

Protein Degradation and InhibitorsTelomeres, Telomerase, and Senescence

Cited by 280

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics

Khan, S., He, Y., Zhang, X., Yuan, Y., Pu, S., Kong, Q., Zheng, G., & Zhou, D. (2020) · Oncogene

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 252

The curcumin analog EF24 is a novel senolytic agent

Li, W., He, Y., Zhang, R., Zheng, G., & Zhou, D. (2019) · Aging

Telomeres, Telomerase, and SenescenceCurcumin's Biomedical Applications

Cited by 164

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

He, Y., Koch, R., Budamagunta, V., Zhang, P., Zhang, X., Khan, S., Thummuri, D., Ortiz, Y. T., Zhang, X., Lv, D., et al. (2020) · Journal of Hematology & Oncology

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 139

Oxidation resistance 1 is a novel senolytic target

Zhang, X., Zhang, S., Liu, X., Wang, Y., Chang, J., Zhang, X., Mackintosh, S. G., Tackett, A. J., He, Y., Lv, D., et al. (2018) · Aging Cell

Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms

Cited by 127

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 126

Osteocyte RANKL is required for cortical bone loss with age and is induced by senescence

Kim, H.-N., Xiong, J., MacLeod, R. S., Iyer, S., Fujiwara, Y., Cawley, K. M., Han, L., He, Y., Thostenson, J. D., Ferreira, E., et al. (2020) · JCI Insight

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 117

Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X L

Zhang, X., Thummuri, D., He, Y., Liu, X., Zhang, P., Zhou, D., & Zheng, G. (2019) · Chemical Communications

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 86

Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines

Zhang, X., He, Y., Zhang, P., Budamagunta, V., Lv, D., Thummuri, D., Yang, Y., Pei, J., Yuan, Y., Zhou, D., et al. (2020) · European Journal of Medicinal Chemistry

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 71

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors

Zhang, X., Li, H., Lv, X., Hu, L., Li, W., Zi, M., & He, Y. (2022) · Life

Cancer Immunotherapy and BiomarkersDietary Effects on Health

Cited by 18

Longevity-Associated Transcription Factor ATF7 Promotes Healthspan by Suppressing Cellular Senescence and Systematic Inflammation

Huang, Y., Ge, M.-X., Li, Y.-H., Li, J.-L., Yu, Q., Xiao, F.-H., Ao, H.-S., Yang, L.-Q., Li, J., He, Y., et al. (2022) · Aging and disease

Genetics, Aging, and Longevity in Model OrganismsTelomeres, Telomerase, and Senescence

Cited by 12